Search results for "survival analysi"

showing 10 items of 752 documents

SPOC1, a novel PHD-finger protein: association with residual disease and survival in ovarian cancer.

2005

We report the identification of a novel human gene (SPOC1) which encodes a protein with a PHD-finger domain. The gene is located in chromosomal region 1p36.23, a region implicated in tumor development and progression. RNA in situ hybridization experiments showed strong SPOC1 expression in some rapidly proliferating cell types, such as spermatogonia, but not in nonproliferating mature spermatocytes. In addition, high SPOC1 mRNA expression was observed in several ovarian cancer cell lines. This prompted us to systematically examine SPOC1 expression in ovarian cancer in relation to prognosis. SPOC1 mRNA expression was quantified in tumor tissue of 103 patients with epithelial ovarian cancer. I…

MaleCancer ResearchCell typePathologymedicine.medical_specialtyMolecular Sequence DataIn situ hybridizationBiologymedicineBiomarkers TumorHumansAmino Acid SequenceRNA MessengerSurvival analysisIn Situ HybridizationAgedCell ProliferationOvarian NeoplasmsProportional hazards modelGene Expression ProfilingMiddle Agedmedicine.diseasePrognosisMinimal residual diseaseSurvival AnalysisSpermatogoniaGene expression profilingDNA-Binding ProteinsOncologyChromosomal regionCancer researchFemaleProteoglycansOvarian cancerInternational journal of cancer
researchProduct

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 2…

2018

This systematic analysis evaluates the cancer burden over time at the global and national levels measured in incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years.

MaleCancer ResearchIncidenceResearchHistory 20th CenturyGlobal HealthHistory 21st CenturySurvival AnalysisGlobal Burden of DiseaseOncologyOncology; Cancer ResearchNeoplasmsHumansOnline FirstFemaleQuality-Adjusted Life YearsOriginal Investigation
researchProduct

DNA image cytometry. A prognostic tool in squamous cell carcinoma of the esophagus?

1991

In 45 patients who underwent an esophagus resection due to a squamous cell carcinoma, in addition to the TNM classification and usual morphologic criteria, the paraffin-embedded material underwent deparaffinization, was rehydrated, and was mechanically and enzymatically processed into a single-cell solution. For evaluating the DNA histogram this was analyzed with the help of automatic single-cell cytophotometric study. The method, contrary to that of flow cytometric study, allows for the selective analysis of tumor cells due to the electronically, previously given selection criteria, whereas artifacts, stroma, and infection cells remain excluded from analysis. The multivariate analysis show…

MaleCancer ResearchPathologymedicine.medical_specialtyEsophageal NeoplasmsTumor cellsResectionStromaEsophagus CarcinomamedicineHumansBasal cellEsophagusDNA Image CytometryNeoplasm StagingPloidiesbusiness.industryDNA NeoplasmPrognosisSurvival Analysismedicine.anatomical_structureOncologyLymphatic MetastasisCarcinoma Squamous CellFemaleCytophotometrybusinessMedian survivalCancer
researchProduct

A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals.

2004

Myelodysplastic syndromes (MDS) show occasionally thrombocytosis, common feature of myeloproliferative diseases (MPD), with the overlapping of both disorders. Classically, thrombocytosis has been associated with some MDS subtypes: refractory anaemia with ringed sideroblasts (RARS), 5q- syndrome and those MDS with 3q chromosome rearrangements. The recent WHO classification recognises an unclassifiable MDS/MPD category including some of these disorders. Our aim is to determine the frequency of presentation, subtype classification and chromosome abnormalities of MDS with thrombocytosis diagnosed in our institution. Between 1990 and 2003 we studied 317 SMD patients according to FAB and WHO revi…

MaleCancer ResearchPathologymedicine.medical_specialtyRefractory anemia with ringed sideroblastsWorld Health OrganizationAge Distributionhemic and lymphatic diseasesInternal medicinemedicineHumansSurvival analysisAgedRetrospective StudiesAged 80 and overThrombocytosisThrombocytosisbusiness.industryMyelodysplastic syndromesRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseSurvival AnalysisOncologyInternational Prognostic Scoring SystemDysplasiaKaryotypingMyelodysplastic SyndromesFemalebusinessRefractory cytopenia with multilineage dysplasiaLeukemia research
researchProduct

Survival of European children and young adults with cancer diagnosed 1995-2002

2009

This study analyses survival in 40,392 children (age 0-14 years) and 30,187 adolescents/young adults (age 15-24 years) diagnosed with cancer between 1995 and 2002. The cases were from 83 European population-based cancer registries in 23 countries participating in EUROCARE-4. Five-year survival in countries and in regional groupings of countries was compared for all cancers combined and for major cancers. Survival for 15 rare cancers in children was also analysed. Five-year survival for all cancers combined was 81% in children and 87% in adolescents/young adults. Between-country survival differences narrowed for both children and adolescents/young adults. Relative risk of death reduced signi…

MaleCancer ResearchPediatricsMESH : Child PreschoolAdolescentsMESH: Epidemiologic Methods[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineMESH : ChildNeoplasmsMESH: ChildEpidemiologyMESH: NeoplasmsMESH : Female030212 general & internal medicineYoung adultChildChildrenChildren & young adults; Cancer survivalMESH : InfantPopulation-based cancer registriesChildren & young adultsMESH: Infant3. Good healthEuropeEastern europeanOncologyMESH: Young AdultChild Preschool030220 oncology & carcinogenesisMESH : Rare DiseasesRare tumoursFemaleMESH: Rare Diseasesmedicine.medical_specialtyAdolescentMESH : MaleMESH : EuropeMESH : Young AdultSocio-culturale[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Epidemiologic MethodsYoung Adult03 medical and health sciencesRare DiseasesSDG 3 - Good Health and Well-beingMESH : AdolescentmedicineHumansPreschoolAdolescents; Cancer survival; Children; Europe; Population-based cancer registries; Rare tumours; Young adults; Adolescent; Child; Child Preschool; Epidemiologic Methods; Europe; Female; Humans; Infant; Male; Neoplasms; Rare Diseases; Young Adult; Oncology; Cancer ResearchSurvival analysisMESH: AdolescentMESH: Humansbusiness.industryMESH: Child PreschoolMESH : HumansInfantCancermedicine.diseaseMESH : NeoplasmsCancer survivalMESH: MaleCancer registryEl NiñoRelative riskMESH: EuropeEpidemiologic MethodsbusinessMESH: FemaleYoung adults
researchProduct

Family circumstances and survival from childhood acute lymphoblastic leukaemia in West Germany

2015

Little is known about the relationship between family characteristics and survival from childhood acute lymphoblastic leukaemia (ALL), which we studied for the first time in German children.ALL cases were diagnosed between 1992 and 1994 and information on family characteristics was collected during a previously conducted nationwide case-control study. Children were followed for 10 years after diagnosis, as few disease-related events occur afterwards. Cox proportional hazards models estimating hazard ratios (HR) were calculated using overall as well as event-free survival methods.Second born children showed statistically significant better survival compared to first or later born children, w…

MaleCancer ResearchPediatricsmedicine.medical_specialtyAdolescentEpidemiologyWest germanyGermanRisk FactorsGermanymedicineHumansChildProportional hazards modelbusiness.industryFamily characteristicsHazard ratioPrecursor Cell Lymphoblastic Leukemia-LymphomaSurvival Analysislanguage.human_languageBirth orderOncologyChild PreschoolAcute DiseaselanguageLymphoblastic leukaemiaFemaleFamily RelationsBirth OrderbusinessCancer Epidemiology
researchProduct

Survival from childhood acute lymphoblastic leukaemia in West Germany: Does socio-demographic background matter?

2013

Sex, age, immunophenotype and white blood cell count at diagnosis are well accepted predictors of survival from acute lymphoblastic leukaemia (ALL) in children. Less is known about the relationship between socio-economic determinants and survival from paediatric ALL, studied here for the first time in German children.ALL cases were diagnosed between 1992 and 1994 and their parents interviewed during a previous nationwide case-control study. Children were followed-up for 10 years after diagnosis by the German Childhood Cancer Registry. Cox proportional hazards models estimating hazard ratios (HRs) were calculated to assess the impact of selected socio-demographic characteristics on overall a…

MaleCancer ResearchPediatricsmedicine.medical_specialtyAdolescentFamily incomeAffect (psychology)GermanRisk FactorsmedicineHumansChildSocioeconomic statusProportional Hazards ModelsChildhood Cancer Registrybusiness.industryProportional hazards modelHazard ratioGermany WestInfantPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisSurvival Analysislanguage.human_languageSocioeconomic FactorsOncologyChild PreschoollanguageLymphoblastic leukaemiaFemalebusinessEuropean Journal of Cancer
researchProduct

Population-based epidemiologic data on brain tumors in German children.

2001

BACKGROUND Brain tumors are the most common disease group of solid tumors in childhood, and children with brain tumors have a relatively poor survival rate. Epidemiologic data from a population-based cancer registry provide the necessary information to obtain a full picture of the frequency of this disease, which is a great challenge in pediatric oncology. METHODS The German Childhood Cancer Registry (GCCR) is a population-based registry. The level of completeness of patient registration is 95%, but it is somewhat lower for patients with brain tumors. More than 300 children with newly diagnosed brain tumors are reported every year. Analyses of GCCR data are performed according to the Intern…

MaleCancer ResearchPediatricsmedicine.medical_specialtyAdolescentPopulationCentral nervous system diseaseGermanymedicineHumansRegistriesAge of OnseteducationChildSurvival rateeducation.field_of_studyChildhood Cancer Registrybusiness.industryBrain NeoplasmsIncidence (epidemiology)IncidenceInfant NewbornCancerInfantmedicine.diseasePrognosisSurvival AnalysisCancer registryEpidemiologic StudiesOncologyChild PreschoolFemaleGerm cell tumorsbusinessCancer
researchProduct

Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib.

2010

Abstract Introduction. Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC). This study was conducted to assess the link between the antitumor efficacy of sorafenib and its early cutaneous side effects in advanced HCC patients. Materials and Methods. All patients received 800 mg daily of sorafenib until progression or unacceptable toxicities. We retrospectively analyzed the incidence of rash and hand–foot skin reactions (HFSR) during the first month of treatment, comparing tumor control (partial response …

MaleCancer ResearchPyridinesSettore MED/06 - Oncologia MedicaKaplan-Meier EstimateGastroenterologySkin Toxicity Hepatocellular CarcinomaSorafenib.Aged 80 and overintegumentary systemIncidence (epidemiology)BenzenesulfonatesLiver NeoplasmsMiddle AgedSorafenibRashhumanitiesOncologyHepatocellular carcinomaToxicityDisease ProgressionFemaleDrug Eruptionsmedicine.symptommedicine.drugAdultNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsInternal medicinemedicineCarcinomaHumansneoplasmsSurvival analysisAgedRetrospective StudiesSurrogate endpointbusiness.industryPhenylurea CompoundsExanthemamedicine.diseaseSurvival Analysisdigestive system diseasesSurgerybody regionsMultivariate AnalysisHepatobiliarybusiness
researchProduct

Complete tumor prevention by engineered tumor cell vaccines employing nonviral vectors.

2004

We report that 100% mice survival after tumor challenge is achieved with cytokine-engineered cells employing nonviral lipoplexes and without using viral vectors. We describe this effect with cytokine-secreting tumor cell vaccines, based on cell clones or fresh transfected cells. Tumor cells were transfected with murine granulocyte-macrophage colony-stimulating factor (GM-CSF) or IL-4 plasmids employing the cationic lipid DOTAP, were irradiated (150 Gy) and kept frozen until use. The transfection efficacy was analyzed by qRT-PCR and flow cytometry. Vaccination induced potent antitumor rejection, resulting in 100% mice survival. Furthermore, the antitumor immunity was long lasting, since a tw…

MaleCancer ResearchSkin NeoplasmsGenetic enhancementCellGenetic VectorsAntineoplastic AgentsBiologyCancer VaccinesViral vectorFlow cytometryMicemedicineAnimalsMolecular BiologyMelanomaInterleukin 4medicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionMelanomaGranulocyte-Macrophage Colony-Stimulating FactorTransfectionGenetic TherapyNeoplasms Experimentalmedicine.diseaseFlow CytometryVirologySurvival AnalysisMice Inbred C57BLmedicine.anatomical_structureGranulocyte macrophage colony-stimulating factorMolecular MedicineFemaleInterleukin-4Genetic Engineeringmedicine.drugCancer gene therapy
researchProduct